Academic literature on the topic 'FIB-4 scores (Fibrosis-4)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'FIB-4 scores (Fibrosis-4).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "FIB-4 scores (Fibrosis-4)"
1
Karic, Uros, Ivana Pesic-Pavlovic, Goran Stevanovic, et al. "FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country's perspective in DAA era." Journal of Infection in Developing Countries 12, no. 03 (2018): 178–82. http://dx.doi.org/10.3855/jidc.10190.
Full textAbstract:
Introduction: Chronic Hepatitis C Virus (HCV) infection leads to progressive fibrosis making fibrosis staging necessary in the evaluation of such patients. Different fibrosis scores are emerging as possible non-invasive alternatives for liver biopsy. The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) scores are the most widely used and the most extensively tested. This study aims to determine if it was possible to accurately use these to identify patients that are unlikely to have severe fibrosis.
 Methodology: One hundred and forty-two patients with chronic hepatitis C infection who underwent liver biopsy since January 1st 2014 until May 31st 2017 at the Hospital for Infectious and Tropical Diseases in Belgrade were analyzed. The FIB-4 and APRI scores were calculated for each patient and compared to histologically determined fibrosis stage.
 Results: A comprehensive statistical analysis was conducted in order to compare patients with and without severe fibrosis and to evaluate the accuracy of the fibrosis scores. Patients with non-severe fibrosis were younger, had higher platelet counts and lower transaminase levels. FIB-4 had an AUC of 0.875 and the APRI score had an AUC of 0.861. No patients with severe fibrosis or cirrhosis had a FIB-4 lower than 1.08. FIB-4 was superior to APRI in identifying patients with severe fibrosis in the study cohort.
 Conclusion: FIB-4 was superior to APRI in the recognition of severe fibrosis. FIB-4 may prove very useful in identifying patients without advanced liver disease, especially if other non-invasive methods are inaccessible.
2
Kumar, Dinesh, Mukulesh Gupta, Kumar Praful Chandra, et al. "FIB-4 score is correlated with liver fibrosis but not with liver steatosis : A Cross-Sectional Study in T2DM patients." International Journal of Medical Science and Clinical Invention 12, no. 01 (2025): 7526–35. https://doi.org/10.18535/ijmsci/v12i.01.01.
Full textAbstract:
Aim: The present study was conducted to evaluate the corelation between Fibrosis-4 score (FIB-4) in cases of Liver fibrosis as well as Liver steatosis in comparison to other liver fibrosis assessment scores. Methodology: Cross-sectional study was conducted amongst 352 participants who had type 2 diabetes mellitus (T2DM). FIB-4 score and Non-alcoholic fatty liver disease fibrosis score (NFS) were calculated using blood parameters and Liver Stiffness Measurement (LSM) scores along with Controlled attenuation parameter (CAP) scores were calculated using Vibration Controlled Transient Elastography (VCTE). Spearman’s correlation estimates were used to evaluate these fibrosis scores of FIB-4, NFS and LSM in Metabolic dysfunction associated steatotic liver disease (MASLD) patients. Results: Out of a total cohort of 352 persons, 75% had steatosis and 27.1% had fibrosis based on the findings of VCTE. According to prediction based on FIB- 4, 10.8% had fibrosis, and based on the NFS fibrosis score 23.4% had fibrosis. Our data revealed a positive correlation between the FIB-4 score and LSM by VCTE (r = 0.22, p < 0.001). Conclusion: Beyond its risk assessment, FIB-4 serves as a prognostic biomarker with clinical significance. This straightforward scoring system can act as an early warning signal, helping to identify patients who are at risk for advanced liver fibrosis and may need referral to specialized medical care.
3
Aydın, Cihan, Nadir Emlek, and Elif Ergül. "Liver fibrosis scores and coronary artery ectasia." Kardiologiia 63, no. 7 (2023): 62–67. http://dx.doi.org/10.18087/cardio.2023.7.n2258.
Full textAbstract:
Background. Although scoring systems showing liver fibrosis using non-invasive methods have been accepted as effective tools for predicting cardiovascular risk, their role in predicting coronary ectasia (CAE) has not been evaluated. This study investigated whether aprison (APRI) and fibrosis-4 indices (FIB-4), which are indicators of fibrosis in nonalcoholic fatty liver disease (NAFLD), are associated with CAE.Material and methods. A retrospective, cross-sectional study consisted of 215 patients, 108 with CAE and 107 without CAE, as diagnosed by angiography. The mean age of all patients was 61.8±9.9 yrs, and 171 (78.8 %) were males. The relationships between APRI, FIB-4, NAFLD, and Bard scores and CAE were evaluated.Results. APRI, FIB-4, NAFLD, and Bard scores were independent predictors of CAE. Fib 4, APRI, NAFLD, and Bard scores were higher in the CAE patients. There were a moderate, positive correlations for FIB-4, APRI, and NAFLD scores with coronary ectasia (r=0.55, p<0.001; r=0.52, p<0.001; r=0.51, p<0.001, respectively). A weak-moderate positive correlation was observed between the Bard score and CAE (r=0.34, p<0.001). Univariate and multivariate regression analysis showed that APRI score, low HDL, and Bard score were independent risk factors for CAE ectasia (p<0.001). Cut-off values to predict CAE as determined by ROC curve analysis were: FIB-4 index ≥1.43 (AUC=0.817, 95 % confidence interval (CI): 0.762 to 0.873, p<0.001), APRI index ≥0.25 (AUC=0.804, 95 % CI: 0.745 to 0.862, p<0.001), NAFLD score ≥–0.92 (AUC=0.798, 95 % CI: 0.738 to 0.857.p<0.001), Bard score ≥2 (AUC=0.691, 95 % CI: 0.621 to 0.761, p<0.001).Conclusion. APRI, FIB-4, NAFLD, and Bard scores are associated with CAE.
4
Cox, Ben, Roberto Trasolini, Ciaran Galts, Eric M. Yoshida, and Vladimir Marquez. "Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease." Canadian Liver Journal 4, no. 3 (2021): 275–82. http://dx.doi.org/10.3138/canlivj-2021-0004.
Full textAbstract:
BACKGROUND: With the rate of non-alcoholic fatty liver disease (NAFLD) on the rise, the necessity of identifying patients at risk of cirrhosis and its complications is becoming ever more important. Liver biopsy remains the gold standard for assessing fibrosis, although costs, risks, and availability prohibit its widespread use with at-risk patients. Transient elastography has proven to be a non-invasive and accurate way of assessing fibrosis, although the availability of this modality is often limited in primary care settings. The Fibrosis-4 (FIB-4) and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) are scoring systems that incorporate commonly measured lab parameters and BMI to predict fibrosis. METHOD: In this study, we compared FIB-4 and NFS scores with transient elastography scores to assess the accuracy of these inexpensive and readily available scoring systems in detecting fibrosis. RESULTS: Using an NFS score cut-off of –1.455 and a FibroScan score cut-off of ≥8.7 kPa, the NFS score had a negative predictive value of 94.1%. Using a FibroScan score cut-off of ≥8.7 kPa, the FIB-4 score had a negative predictive value of 91.6%. CONCLUSION: The NFS and FIB-4 are non-invasive, inexpensive scoring systems that have high negative predictive value for fibrosis compared with transient elastography scores. These findings suggest that the NFS and FIB-4 can provide adequate reassurance to rule out fibrosis in patients with NAFLD and can be used with select patients to circumvent the need for transient elastography or liver biopsy.
5
AÇIKALIN ARIKAN, Hatice Burcu, Tuna DEMİRDAL, and Neriman BİLİR. "Kronik hepatit C’li hastaların karaciğer fibrozisini göstermede APRI ve FIB-4 skorlamalarının değeri." Cukurova Medical Journal 48, no. 2 (2023): 663–68. http://dx.doi.org/10.17826/cumj.1273431.
Full textAbstract:
Purpose: Infection with hepatitis C virus causes chronic liver damage, fibrosis and in later processes, cirrhosis and liver cancer. Currently, the use of biomarkers, instead of invasive procedures, is recommended to identify liver fibrosis. In this study, we aimed to evaluate the sensitivity and specificity of aspartate aminotransferase (AST) to Platelet Ratio Index (APRI) and Fibrosis-4 Index (FIB-4) scoring for detection of "significant fibrosis" in chronic hepatitis C patients.
 Materials and Methods: Liver biopsy results and blood test results of 50 patients, infected with chronic hepatitis C, were analyzed. APRI and FIB-4 scores were calculated. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency for APRI and FIB-4 scorings were calculated using a fourfold table. The values of APRI and FIB-4, providing the best specificity and sensitivity in the diagnosis of significant fibrosis, was determined by ROC (receiver operator characteristics curve) analysis.
 Results: The mean fibrosis stage of 30 patients with significant fibrosis was 2.83±0.74 and the mean patient age was 56.8±13. The sensitivity of APRI ≥ 1.5 to detect significant fibrosis was 16%, the specificity was 90%, PPV was 71% and NPV was 41%. A FIB-4 score of ≥3.25 had a sensitivity of 20%, a specificity of 95%, a PPV of 85% and a NPV of 44%. 
 Conclusion: APRI and FIB-4 have high specificity and PPV in demonstrating significant fibrosis, but have low sensitivity and NPV. The sensitivity of FIB-4 was higher compared to the APRI scoring. More research on this subject is needed, as well as revision of fibrosis scores and development of new fibrosis scores.
6
Cox, B. D., R. Trasolini, C. Galts, E. M. Yoshida, and V. Marquez. "A188 COMPARING THE PERFORMANCE OF FIBROSIS-4 (FIB-4) AND NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE (NFS) WITH FIBROSCAN SCORES IN NON-ALCOHOLIC FATTY LIVER DISEASE." Journal of the Canadian Association of Gastroenterology 3, Supplement_1 (2020): 59–60. http://dx.doi.org/10.1093/jcag/gwz047.187.
Full textAbstract:
Abstract Background With the rates of non-alcoholic fatty liver disease (NAFLD) on the rise, the necessity of identifying patients at risk of cirrhosis and its complications is becoming ever more important. Liver biopsy remains the gold standard for assessing fibrosis, although the costs, risks, and availability prohibit its widespread use for at-risk patients. Fibroscan has proven to be a non-invasive and accurate way of assessing fibrosis, although the availability of this modality is often limited in the primary care setting. The Fibrosis-4 (FIB-4) and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) are scoring systems which incorporate commonly measured lab parameters and BMI to predict fibrosis. In this study, we compared FIB-4 and NFS values to fibroscan scores to assess the accuracy of these inexpensive and readily available scoring systems for detecting fibrosis. Aims The aim of this study was to determine if non-invasive and inexpensive scoring systems (FIB-4 and NFS) can be used to rule out fibrosis in non-alcoholic fatty liver disease with comparable efficacy to fibroscan. Ultimately, we aim to demonstrate that these scoring systems can be used as an alternative to fibroscan in some patients. Methods Data was collected from 317 patient charts from the Vancouver General Hepatology Clinic. 93 patients were removed from the study due to insufficient data (missing Fibroscan score or lab work necessary for FIB-4/NFS). For the remaining 224 patients, FIB-4 and NFS were calculated and compared to fibrosis scores both independently and in combination. Results: Using a NFS score cut-off of -1.455 and a fibroscan score cut-off of ≥8.7kPa, the NFS had a sensitivity of 71.9%, a specificity of 75%, and a negative predictive value of 94.1%. For a fibroscan score cut-off of ≥8.0kPa, the NFS had a sensitivity of 66.7%, a specificity of 75.7%, and a negative predictive value of 91.5%. Using a fibroscan score cut-off of ≥8.7kPa, the FIB-4 score had a sensitivity of 53.1%, specificity of 84.9%, and a negative predictive value of 91.6%. For a cut-off of ≥8.0kPa, it had a sensitivity of 51.3%, and 85.9%, and a negative predictive value of 89.3%. Conclusions: The NFS and FIB-4 are non-invasive scoring systems that have high sensitivity and negative predictive value for fibrosis when compared to fibroscan scores. These findings suggest that the NFS and FIB-4 can provide adequate reassurance to rule-out fibrosis in select patients, and has promising use in the primary care setting where fibroscan access is often limited. Funding Agencies None
7
Åberg, Fredrik, Mitja Lääperi, and Ville Männistö. "CLivD score modifies FIB-4 performance in liver fibrosis detection in the US general population." eGastroenterology 1, no. 2 (2023): e100035. http://dx.doi.org/10.1136/egastro-2023-100035.
Full textAbstract:
Background and aimsSteatotic liver disease (SLD) is a growing global concern. The Chronic Liver Disease (CLivD) risk score predicts liver-related outcomes in the general population using easily accessible variables with or without laboratory tests (CLivDlaband CLivDnon-lab). We assessed CLivD’s associations with liver steatosis, fibrosis and its combined performance with fibrosis-4 (FIB-4) for advanced fibrosis detection.MethodsUsing the National Health and Nutrition Examination Survey data (2017–2020), 3603 participants aged 40–70 years with valid liver stiffness measurements (LSMs) were included. Advanced fibrosis was defined as LSM ≥12 kPa, and SLD as controlled attenuation parameter ≥288 dB/m.ResultsSignificant associations were found between CLivD and SLD and advanced fibrosis. CLivDlabhad an area under the curve (AUC) for advanced fibrosis of 0.72 (95% CI 0.68 to 0.77), while CLivDnon-labhad an AUC of 0.68 (95% CI 0.64 to 0.72), both slightly higher than FIB-4 (AUC 0.66, 95% CI 0.60 to 0.72). Among participants without obesity, AUC of CLivDlabwas 0.82 (95% CI 0.76 to 0.88) and AUC of CLivDnon-labwas 0.72 (95% CI 0.65 to 0.79). The CLivD score improved FIB-4’s AUC for advanced fibrosis detection from <0.5 at minimal CLivD scores to >0.8 at high CLivD scores. A sequential CLivD→FIB-4 strategy outperformed universal FIB-4 testing, enhancing specificity from 72% to 83%, with sensitivity at 51%–53%. This strategy identified a subgroup with a 55% prevalence of advanced fibrosis, while 47% had minimal-risk CLivD scores, eliminating the need for FIB-4 testing.ConclusionsThe CLivD score, designed for predicting liver-related outcomes, effectively identifies liver steatosis and advanced fibrosis in the general population. Combining CLivD with FIB-4 enhances advanced fibrosis detection accuracy. The CLivD score could enhance population-based liver fibrosis screening, optimising resource allocation.
8
Naik, B. Balakasi, Babu Kumar, and Sultan Nawahirsha Pughazhendhi. "Serum fibroscores APRI, FIB-4 and fibroscan in assessment of liver fibrosis in alcoholic associated liver disease." International Journal of Advances in Medicine 8, no. 4 (2021): 551. http://dx.doi.org/10.18203/2349-3933.ijam20211054.
Full textAbstract:
Background: Alcohol-associated liver disease includes a variety of clinical disorders which include steatosis, Alcoholic steato hepatitis, alcoholic hepatitis of varying degrees of severity, alcoholic cirrhosis, and alcohol associated cirrhosis complicated by hepatocellular carcinoma (HCC). In patients with alcoholic liver disease the presence of hepatic (liver) fibrosis and progression into cirrhosis is a prognostic variable and having impact on survival. To assess hepatic (liver) fibrosis using serum fibro scores fibrosis-4 (FIB-4) scores, AST platelet ratio index (APRI scores) and to compare these results with fibro scan to rule out severe fibrosis in patients with alcohol related disease.Methods: A cross sectional clinical study conducted on 50 patients with alcohol associated chronic liver disease between December 2019 to December 2020 who were in follow up in outpatient department (OPD) and admitted in the Department of Medical Gastroenterology. APRI and FIB-4 scores were calculated and compared with fibro scan values.Results: The results of 50 patients were analysed, including, males with a mean age. Among the study population, 6 (12%) participants had no significant FIB-4, 16 (32%) participants had intermediate FIB-4 and 28 (56%) participants had likely cirrhosis. 33 (66%) participants had no significant APRI, 6 (12%) participants had significant APRI and 11 (22%) participants had cirrhosis liver. Among the people with fibro scan KPA F0-F1 (<7), all of them 100% were no significant FIB-4. Among the people with fibro scan KPA F2 (7 To 9.50), 2 (50%) were no significant FIB-4 and intermediate FIB-4 for each respectively.Conclusions: FIB-4 score correlated better than APRI score in assessing patients with and without severe fibrosis and cirrhosis in the setting of alcohol associated liver disease patients.
9
Kolhe, Kailash Marotrao, Anjali Amarapurkar, Pathik Parikh, et al. "Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population." BMJ Open Gastroenterology 6, no. 1 (2019): e000288. http://dx.doi.org/10.1136/bmjgast-2019-000288.
Full textAbstract:
Background and aimsNon-invasive assessment of fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is challenging, especially in resource-limited settings. MR or transient elastography and many patented serum scores are costly and not widely available. There are limited data on accuracy of serum-based fibrosis scores in urban slum-dwelling population, which is a unique group due to its dietary habits and socioeconomic environment. We did this study to compare the accuracy of serum-based fibrosis scores to rule out significant fibrosis (SF) in this population.MethodsHistological and clinical data of 100 consecutive urban slum-dwelling patients with NAFLD were analysed. Institutional ethics committee permission was taken. Aspartate transaminase (AST) to platelet ratio index (APRI), fibrosis-4 index (FIB-4) and FIB-5 scores were compared among those with non-significant fibrosis (METAVIR; F0 to F1; n=73) and SF (METAVIR; F2 to F4; n=27).ResultsAST (IU/mL) (68.3±45.2 vs 23.9±10.9; p<0.0001), alanine transaminase (IU/mL) (76.4±36.8 vs 27.9±11.4; p<0.0001), FIB-4 (2.40±2.13 vs 0.85±0.52; p<0.0001) and APRI (1.18±0.92 vs 0.25±0.16; p<0.0001) were higher and platelets (100 000/mm3) (1.8±0.8 vs 2.6±0.7; p<0.0001), albumin (g/dL) (3.4±0.50 vs 3.7±0.4; p<0.0001), alkaline phosphatase (IU/L) (60.9±10.2 vs 76.4±12.9; p<0.0001) and FIB-5 (−1.10±6.58 vs 3.79±4.25; p<0.0001) were lower in SF group. APRI had the best accuracy (area under the receiver operating characteristic curve=0.95) followed by FIB-4 (0.78) and FIB-5 (0.75) in ruling out SF.ConclusionsAPRI but not FIB-5 or FIB-4 is accurate in ruling out SF in patients with NAFLD in an urban slum-dwelling population.
10
Demir, Nurhan, Bilgehan Yüzbasıoglu, Turan Calhan, and Savas Ozturk. "Prevalence and Prognostic Importance of High Fibrosis-4 Index in COVID-19 Patients." International Journal of Clinical Practice 2022 (May 4, 2022): 1–8. http://dx.doi.org/10.1155/2022/1734896.
Full textAbstract:
Introduction. The fibrosis 4 (FIB-4) index was developed to predict advanced fibrosis in patients with liver disease. We aimed to evaluate the association of FIB-4 with risk factors for progression to critical illness in middle-aged patients hospitalized for coronavirus disease 2019 (COVID-19). Method. We included patients aged 35–65 years who were hospitalized following a positive RT-PCR SARS-Cov-2 test in a tertiary hospital. All data were obtained from the medical records of the patients during the first admission to the hospital. The FIB-4 index was calculated according to the equation (age (years) x AST (IU/L)/platelet count (109/L)/√ALT (IU/L)). The FIB-4 index was divided into three categories according to the score categorisation: <1.3 = low risk, 1.3–2.67 = moderate risk, and >2.67 = high risk. Results. A total of 619 confirmed COVID-19 patients (mean age = 52 yrs.) were included in this study; 37 (6.0%) were admitted to the intensive care unit (ICU), of which 44% were intubated and eight (1.3%) patients died during follow-up. The results of patients with high FIB-4 scores were compared with those with low FIB-4 scores. In patients with high FIB-4 scores, male gender, and advanced age, decreased neutrophil, lymphocyte, thrombocyte, and albumin counts, elevated AST, LDH, CK, ferritin, CRP, and D-dimer, and low GFR were the high-risk factors for critical illness. Additionally, the number of patients referred to ICU with high FIB-4 who died had higher scores than from those with low scores. Conclusion. The FIB-4 index derived from baseline data obtained during hospitalisation can be used as a simple, inexpensive, and straightforward indicator to predict ICU requirement and/or death in middle-aged hospitalized COVID-19 patients.
Book chapters on the topic "FIB-4 scores (Fibrosis-4)"
1
Cerda-Reyes, Eira, Alicia Sarahi Ojeda-Yuren, Julián Torres-Vazquez, et al. "Diagnosis of Nonalcoholic Steatohepatitis." In Advances in Hepatology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96281.
Full textAbstract:
The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in the last years up to 25% in the adult population. This disease includes a large spectrum of disorders, from simple fatty liver disease to cirrhosis and Hepatocellular Carcinoma (HCC), and they are related to chronic metabolic conditions. NAFLD is characterized by the presence of at least 5% of hepatic steatosis without evidence of hepatocellular injury. The diagnosis of this disease should be of exclusion and focused on its progression, treatment, and identification of the prognosis. The European Association for the Study of the Liver (EASL), the National Institute for Health and Care Excellence (NICE), the Italian Association for the Study of the Liver (AISF), and the American Association for the Study of the Liver (AASLD), published their Clinical Guidelines that have identified the criteria for the diagnosis of NAFLD, several, using imaging or histological diagnostic methods, although they imply a different approach and screening. The Fatty Liver Index and the NAFLD Liver Fat Score are used by 3 out of 5 Guidelines and they are easily calculated using blood tests and clinical information. Other non-invasive scales for NAFLD are the NAFLD fibrosis score (NFS), Fib-4, AST/ALT ratio index; also the ELF panel, Fibrometer, Fibrotest, Hepascore; and some imaging techniques that include transient elastography, magnetic resonance elastography (MRE), and shear wave elastography. Finally, proteomic’s and glycomic’s technologic biomarkers are currently under investigation and recent use, such as Cytokeratin 18 and Sirtuin 1. Still, liver biopsy remains the gold standard to distinguish between steatohepatitis and simple steatosis, using the histological classification and staging scoring systems of NAFLD Activity Score (NAS) and the Steatosis Activity Fibrosis (SAF), to evaluate the disease’s activity.
Conference papers on the topic "FIB-4 scores (Fibrosis-4)"
1
Paternostro, R., A. Stättermayer, M. Trauner, P. Ferenci, and A. Ferlitsch. "Transient elastography, APRI and FIB-4 scores for staging of fibrosis and cirrhosis in Wilson disease." In 51. Jahrestagung & 29. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1654665.
Full text
2
Richter, M., A. Zipprich, T. Caldonazo, H. Kirov, S. Bargenda, and T. Doenst. "Liver Fibrosis Assessed by Fib-4 Score Unmasks Beneficial Effects of Off-Pump over On-Pump CABG." In 53rd Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1780594.
Full textReports on the topic "FIB-4 scores (Fibrosis-4)"
1
Sowjanya, Dr Kaniti, Dr Bongu Srinivas, and Dr Metta Lakshmana Rao. A STUDY ON FIBROSCAN COMPARED TO AST TO PLATELET RATIO INDEX(APRI) FOR ASSESSMENT OF LIVER FIBROSIS WITH NONALCOHOLIC FATTY LIVER DISEASE(NAFLD). World Wide Journals, 2023. http://dx.doi.org/10.36106/ijar/1606016.
Full textAbstract:
Background : Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a cause of chronic liver disease, and often results in the devastating outcomes of decompensated liver cirrhosis and hepatocellular carcinoma and is an important feature of metabolic syndromes and insulin resistance. The assessment of liver brosis is essential for predicting the prognosis and outcome of all forms of chronic liver disease. A liver biopsy is the gold standard for the assessment of liver brosis, but it has its limitations, which include life-threatening complications. Alternative methods of non-invasive laboratory and radiological testing for the assessment of liver brosis in NAFLD have evolved during the past decade, and these methods may be able to overcome the limitations of liver biopsy. These methods include the AST/ALT ratio, the AST platelet ratio index (APRI), and the Fibrosis 4 (FIB-4) score. This study was conducted in order to assess liver brosis using Fibroscan, and to compare these results to the use of AST platelet ratio index (APRI scores), and the AST/ALT ratios on NAFLD patients. METHODS: This was a cross sectional study conducted in King George Hospital Visakhapatnam,A total 122 patients were studied of which 65 were males and 57 were females.all the patients were subjected to relevant investigations including ultrasound abdomen,serum liver enzymes,broscan. The (SPSS) version 20 was used for the analysis.A Student's t-test was used to compare the AST/ALT ratio to the APRI scores between patients with advanced brosis higher than F2 and patients with mild to moderate brosis of F2 or less. RESULTS :The data showed that a high percentage of the NAFLD patients exhibited advanced stages of liver brosis based on the Fibroscan examinations. These results were supported by the strong correlation between the Fibroscan results and the AST/ALT ratio and APRI scores. Correlation analysis showed a signicant positive correlation between age and brosis scores (r = 0.27 with P = 0.004 for Pearson correlations). On the other hand, a signicant negative correlation between platelet count and stiffness scores was obtained (r = - 0.315 with P= 0.001 for Pearson correlations). Serum ALT level was determined to be signicantly negatively correlated with age by using Spearman correlations (r = - 0.232, and P = 0.022). A signicant positive correlation was observed between serum ALT and hepatic stiffness measurements using Spearman correlations (r = 0.284, and P = 0.005). This study has shown that the combination of Fibroscan CONCLUSION: and AST/ALT and APRI methods provides a valuable approach for assessing liver brosis in NAFLD patients. This can eliminate the need for liver biopsy in patients without clear indication